MCID: END062
MIFTS: 47

Endometrial Hyperplasia

Categories: Cancer diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Endometrial Hyperplasia

MalaCards integrated aliases for Endometrial Hyperplasia:

Name: Endometrial Hyperplasia 11 53 43 14 75

Classifications:



External Ids:

Disease Ontology 11 DOID:0080365
MeSH 43 D004714

Summaries for Endometrial Hyperplasia

Disease Ontology: 11 An uterine benign neoplasm that is characterized by excessive proliferation of the cells of the endometrium.

MalaCards based summary: Endometrial Hyperplasia is related to endometrial adenocarcinoma and adenomyosis. An important gene associated with Endometrial Hyperplasia is PGR (Progesterone Receptor), and among its related pathways/superpathways are Gene expression (Transcription) and Signal Transduction. The drugs Medroxyprogesterone acetate and Contraceptive Agents, Male have been mentioned in the context of this disorder. Affiliated tissues include uterus, pituitary and ovary, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435)

Wikipedia: 75 Endometrial hyperplasia is a condition of excessive proliferation of the cells of the endometrium, or... more...

Related Diseases for Endometrial Hyperplasia

Diseases related to Endometrial Hyperplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 390)
# Related Disease Score Top Affiliating Genes
1 endometrial adenocarcinoma 31.1 PTEN PGR MSH6 MSH2 MLH1 KRAS
2 adenomyosis 31.0 PTEN KRAS ESR1 CYP19A1 CTNNB1
3 myoma 30.8 PGR KRAS ESR1 CYP19A1
4 adenocarcinoma 30.7 PTEN MSH6 MSH2 MLH1 KRAS CTNNB1
5 estrogen excess 30.7 PTEN PGR ESR2 ESR1 CYP19A1
6 endometriosis 30.7 PTEN PGR ESR2 ESR1 CYP19A1 CYP17A1
7 vaginal discharge 30.7 PGR ESR1 CYP19A1
8 adenomyoma 30.6 PGR MLH1 ESR1 CTNNB1
9 lynch syndrome 1 30.6 MSH6 MSH2 MLH1
10 ovarian cyst 30.6 PGR MSH2 ESR2 ESR1 CYP19A1
11 leiomyoma, uterine 30.4 PGR ESR2 ESR1 CYP19A1
12 mismatch repair cancer syndrome 1 30.4 PTEN MSH6 MSH2 MLH1 CTNNB1
13 lynch syndrome 30.3 PTEN PGR MSH6 MSH2 MLH1 KRAS
14 vaginal cancer 30.3 PTEN PGR ESR1
15 infertility 30.3 PGR MLH1 ESR2 ESR1 CYP19A1 AR
16 hyperandrogenism 30.3 CYP19A1 CYP17A1 AR
17 papillary serous adenocarcinoma 30.3 PGR KRAS ESR1
18 adenosarcoma 30.3 PGR MKI67 ESR1
19 mismatch repair cancer syndrome 30.2 PTEN MSH6 MSH2 MLH1 KRAS CTNNB1
20 carcinosarcoma 30.2 PTEN PGR KRAS CTNNB1
21 pelvic organ prolapse 30.2 ESR2 ESR1 CTNNB1
22 cystadenocarcinoma 30.2 PTEN PGR KRAS ESR2
23 inherited cancer-predisposing syndrome 30.2 PTEN MSH6 MSH2 MLH1
24 bap1 tumor predisposition syndrome 30.2 PTEN MSH6 MSH2 MLH1
25 endometrial stromal sarcoma 30.2 PGR ESR2 ESR1 CYP19A1
26 cervical adenocarcinoma 30.2 PGR MKI67 KRAS ESR1
27 teratoma 30.1 PTEN KRAS ESR1 CTNNB1
28 leydig cell tumor 30.1 ESR1 CYP19A1 CYP17A1
29 appendix adenocarcinoma 30.1 MSH6 KRAS
30 acne 30.1 CYP19A1 CYP17A1 AR
31 leiomyoma 30.0 PGR MKI67 ESR2 ESR1 CYP19A1 CYP17A1
32 meningioma, familial 30.0 PTEN PGR MKI67 ESR1 CTNNB1
33 serous cystadenocarcinoma 29.9 PTEN PGR MSH6 MSH2 MLH1 KRAS
34 estrogen-receptor positive breast cancer 29.9 PTEN PGR ESR2 ESR1 CYP19A1 AR
35 adenoma 29.7 MSH6 MSH2 MLH1 MKI67 KRAS CTNNB1
36 uterine carcinosarcoma 29.7 PTEN MSH6 MSH2 MLH1 KRAS ESR1
37 premature menopause 29.6 PTEN PGR ESR2 ESR1 CYP19A1 CYP17A1
38 uterine corpus cancer 29.6 PTEN PGR MSH6 MSH2 MLH1 KRAS
39 endometrial cancer 29.5 PTEN PGR NCOA3 NCOA1 MSH6 MSH2
40 ovarian disease 29.5 PTEN PGR ESR2 ESR1 CYP19A1 CYP17A1
41 ovarian cancer 28.0 RBP1 PTEN PGR NCOA3 MSH6 MSH2
42 breast cancer 27.5 PTEN PGR NCOR1 NCOA3 NCOA1 MSH6
43 polycystic ovary syndrome 10.6
44 polycystic ovary syndrome 1 10.5
45 breast duct papilloma 10.4 PTEN PGR
46 nipple carcinoma 10.4 PGR ESR1
47 bartholin's gland adenoma 10.4 PGR ESR1
48 uterine corpus adenosarcoma 10.4 PGR ESR1
49 breast mucinous cystadenocarcinoma 10.4 PGR ESR1
50 bartholin's gland benign neoplasm 10.4 PGR ESR1

Graphical network of the top 20 diseases related to Endometrial Hyperplasia:



Diseases related to Endometrial Hyperplasia

Symptoms & Phenotypes for Endometrial Hyperplasia

GenomeRNAi Phenotypes related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

25 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.2 AR CABLES1 CDK2 CTNNB1 CYP17A1 CYP19A1
2 no effect GR00402-S-2 10.2 AR CABLES1 CDK2 CTNNB1 CYP17A1 CYP19A1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.02 CABLES1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.02 NCOR1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.02 MSH2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.02 KRAS
7 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.02 NCOR1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-14 10.02 MSH2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-145 10.02 CABLES1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.02 MSH2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.02 CABLES1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.02 MSH2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.02 CABLES1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.02 CABLES1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.02 CABLES1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-212 10.02 NCOR1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.02 MSH2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.02 KRAS
19 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.02 NCOR1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.02 NCOR1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.02 MSH2 NCOR1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.02 CABLES1 KRAS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.02 CABLES1
24 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.55 ESR1 ESR2 MKI67 MSH2 PTEN

MGI Mouse Phenotypes related to Endometrial Hyperplasia:

45 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.5 AR CDK2 CTNNB1 CYP17A1 CYP19A1 ESR1
2 neoplasm MP:0002006 10.46 AR CABLES1 CDK2 CTNNB1 ESR1 ESR2
3 endocrine/exocrine gland MP:0005379 10.39 AR CABLES1 CDK2 CTNNB1 CYP19A1 ESR1
4 nervous system MP:0003631 10.38 AR CABLES1 CTNNB1 CYP19A1 ESR1 ESR2
5 growth/size/body region MP:0005378 10.37 AR CDK2 CTNNB1 CYP17A1 CYP19A1 ESR1
6 normal MP:0002873 10.35 AR CTNNB1 CYP19A1 ESR1 ESR2 KRAS
7 cellular MP:0005384 10.33 AR CDK2 CTNNB1 CYP17A1 CYP19A1 ESR1
8 muscle MP:0005369 10.32 AR CDK2 CTNNB1 CYP19A1 ESR1 ESR2
9 liver/biliary system MP:0005370 10.32 AR CDK2 CTNNB1 CYP19A1 ESR1 ESR2
10 immune system MP:0005387 10.3 AR CDK2 CTNNB1 CYP19A1 ESR1 ESR2
11 behavior/neurological MP:0005386 10.25 AR CABLES1 CTNNB1 CYP17A1 CYP19A1 ESR1
12 renal/urinary system MP:0005367 10.24 AR CTNNB1 CYP19A1 ESR1 ESR2 KRAS
13 adipose tissue MP:0005375 10.21 AR CYP17A1 CYP19A1 ESR1 ESR2 NCOA1
14 reproductive system MP:0005389 10.2 AR CABLES1 CDK2 CTNNB1 CYP17A1 CYP19A1
15 embryo MP:0005380 10.19 AR CDK2 CTNNB1 ESR1 KRAS NCOA1
16 digestive/alimentary MP:0005381 10.18 AR CTNNB1 CYP19A1 ESR1 ESR2 KRAS
17 cardiovascular system MP:0005385 10.17 AR CDK2 CTNNB1 CYP17A1 CYP19A1 ESR1
18 limbs/digits/tail MP:0005371 10.11 AR CTNNB1 ESR1 ESR2 KRAS PGR
19 pigmentation MP:0001186 10.09 AR CTNNB1 CYP19A1 KRAS PTEN RBP1
20 hearing/vestibular/ear MP:0005377 10.08 CTNNB1 CYP17A1 CYP19A1 ESR2 KRAS NCOA3
21 hematopoietic system MP:0005397 10.03 AR CDK2 CTNNB1 CYP19A1 ESR1 ESR2
22 skeleton MP:0005390 10 AR CTNNB1 CYP17A1 CYP19A1 ESR1 ESR2
23 mortality/aging MP:0010768 9.8 AR CDK2 CTNNB1 CYP17A1 ESR1 ESR2
24 integument MP:0010771 9.5 AR CDK2 CTNNB1 CYP19A1 ESR1 ESR2

Drugs & Therapeutics for Endometrial Hyperplasia

Drugs for Endometrial Hyperplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Medroxyprogesterone acetate Approved, Investigational Phase 4 520-85-4, 71-58-9 6279 10631
2 Contraceptive Agents, Male Phase 4
3 Estrogens, Conjugated (USP) Phase 4
4 BIRC5 protein, human Phase 4
5
Bazedoxifene Approved, Investigational Phase 3 198481-32-2 154257
6
Raloxifene Approved, Investigational Phase 3 82640-04-8, 84449-90-1 5035
7
Metformin Approved Phase 2, Phase 3 1115-70-4, 657-24-9 4091
8
Levonorgestrel Approved, Investigational Phase 2, Phase 3 797-63-7 13109
9
Dydrogesterone Approved, Investigational, Withdrawn Phase 2, Phase 3 152-62-5 9051
10
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
11
Estradiol Approved, Investigational, Vet_approved Phase 2, Phase 3 50-28-2 5757
12
Polyestradiol phosphate Approved Phase 2, Phase 3 28014-46-2
13
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
14
Ethinylestradiol Approved Phase 2, Phase 3 57-63-6 5991
15
Cyproterone acetate Approved, Investigational Phase 2, Phase 3 427-51-0 9880
16 Estrogen Receptor Modulators Phase 3
17 Selective Estrogen Receptor Modulators Phase 3
18
Rosuvastatin Calcium Phase 2, Phase 3 147098-20-2
19 Antimetabolites Phase 2, Phase 3
20 Calcium, Dietary Phase 2, Phase 3
21 Hypolipidemic Agents Phase 2, Phase 3
22 Anticholesteremic Agents Phase 2, Phase 3
23 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2, Phase 3
24 Lipid Regulating Agents Phase 2, Phase 3
25 Progestins Phase 3
26 Estradiol 3-benzoate Phase 2, Phase 3
27 Estradiol 17 beta-cypionate Phase 2, Phase 3
28
Cyproterone Phase 2, Phase 3 2098-66-0 5284537
29 Androgens Phase 2, Phase 3
30 Androgen Antagonists Phase 2, Phase 3
31 Cyproterone acetate, ethinyl estradiol drug combination Phase 2, Phase 3
32
Calcium Nutraceutical Phase 2, Phase 3 7440-70-2 271
33
Norethisterone Approved Phase 2 68-22-4 199472 6230
34
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
35
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
36
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
37
Genistein Investigational Phase 2 446-72-0 5280961
38
Norethindrone Acetate Phase 2 541197
39 Soy Bean Phase 2
40 Gonadotropins, Pituitary Phase 2
41 Immunosuppressive Agents Phase 2
42 Immunologic Factors Phase 2
43 Hormones Phase 2
44 Hormone Antagonists Phase 2
45 Estrogens Phase 2
46 Estrogen Receptor Antagonists Phase 2
47 Estrogen Antagonists Phase 2
48 Aromatase Inhibitors Phase 2
49
Formaldehyde Approved, Vet_approved 50-00-0 712
50
Tamoxifen Approved 10540-29-1, 54965-24-1 2733526

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 A Multicenter Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia Completed NCT01074892 Phase 4 Provera (medroxyprogesterone/progestin);Provera (medroxyprogesterone)
2 The Effect of Metformin and Medroxyprogesterone Acetate on Apoptotic Signaling Pathways in Wistar-Albino Rats With Induced Endometrial Hyperplasia Completed NCT02872818 Phase 4 17β estradiol hemihydrate;Metformin;medroxyprogesterone acetate
3 Randomized, Blinded Trial Comparing Vaginal Estrogens on Pelvic Organ Prolapse Patients Completed NCT03032848 Phase 4 Conjugated Estrogen;Promestriene;Estriol;Vaginal Moisturizer - Cream
4 A Double-Blind, Randomized, Placebo And Active- Controlled Efficacy And Safety Study Of The Effects Of Bazedoxifene/Conjugated Estrogens Combinations On Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women Completed NCT00808132 Phase 3 bazedoxifene 20 mg/ conjugated estrogens 0.45 mg;bazedoxifene 20 mg/ conjugated estrogens 0.625 mg;bazedoxifene 20 mg;conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg;Placebo
5 A Double-Blind, Randomized, Placebo- And Active-Controlled Efficacy And Safety Study Of Bazedoxifene/Conjugated Estrogens Combinations For Prevention Of Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women Completed NCT00242710 Phase 3 Bazedoxifene/Conjugated Estrogen;CE 0.45 mg/MPA 1.5mg
6 Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia Completed NCT04491682 Phase 2, Phase 3 Megestrol Acetate;Rosuvastatin
7 A Double-Blind, Randomized, Placebo- and Active-Controlled Safety and Efficacy Study of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women Completed NCT00675688 Phase 3 Bazedoxifene/Conjugate Estrogens (CE);Raloxifene;Placebo
8 Operational Hysteroscopy Versus Traditional Surgery: Costs and Health Benefits Completed NCT00490087 Phase 3
9 Megestrol Acetate Plus LNG-IUS to Megestrol Acetate or LNG-IUS in Young Women With Endometrial Atypical Hyperplasia Completed NCT03241888 Phase 2, Phase 3 Megestrol Acetate
10 The Efficacy of Levonorgestrel Intrauterine System Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia. A Randomized Controlled Trial. Recruiting NCT04385667 Phase 2, Phase 3 Oral Megesterol 160 mg daily
11 Medroxyprogesterone Acetate (MPA) Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia Recruiting NCT03675139 Phase 2, Phase 3 Medroxyprogesterone Acetate;Dydrogesterone 10 MG
12 MicroRNAs as Biomarkers of Predicting Future Endometrial Malignancy and Longitudinal Follow-up With Randomized Intervention in Women With Endometrial Hyperplasia Without Atypia Recruiting NCT05292573 Phase 3 Metformin
13 Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia: A Non-Inferiority Study Recruiting NCT04897217 Phase 3 Megestrol Acetate;Levonorgestrel Drug Implant
14 Value of Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Fertility-preserving Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma Recruiting NCT03463252 Phase 2, Phase 3 Progesterone;GnRH agonist
15 Weight Management Plus Levonorgestrel Intrauterine System or Megestrol Acetate in Endometrial Atypical Hyperplasia: Multiple Single-arm, Prospective and Open-label Clinical Study Recruiting NCT05316493 Phase 2, Phase 3 Megestrol Acetate 160 MG Oral Tablet;Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg
16 Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole vs Ethinylestradiol Cyproterone Plus Metformin in Progestin-insensitive Early-stage Endometrial Cancer and Atypical Hyperplasia Patients With Conservative Treatment Recruiting NCT05316935 Phase 2, Phase 3 GnRHa;Letrozole 2.5mg;Diane-35;MET
17 A Randomized Controlled Pilot Study of Polyethylene Glycol Loxenatide Plus LNG-IUS in Women With Endometrial Atypical Hyperplasia Recruiting NCT05172999 Phase 2, Phase 3 Polyethylene Glycol Loxenatide
18 Comparing Metformin Plus Megestrol Acetate With Megestrol Acetate Alone as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia Terminated NCT04607252 Phase 2, Phase 3 Metformin plus Megestrol acetate;Megestrol Acetate
19 Megestrol Acetate Versus Liraglutide Plus Megestrol Acetate in Obese Women With Endometrial Atypical Hyperplasia: A Randomized Controlled Pilot Clinical Study Withdrawn NCT04683237 Phase 2, Phase 3 Liraglutide Injection;Megestrol Acetate 160 MG
20 Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System:Single Arm, Prospective Multicenter Study: Korean Gynecologic Oncology Group Study (KGOG2006) Unknown status NCT01234818 Phase 2
21 A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium Unknown status NCT01686126 Phase 2 Levonorgestrel;Metformin
22 Efficacy & Tolerability of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen Replacement Therapy - Phase II Comparative Study Unknown status NCT00919919 Phase 2 progesterone;activella
23 Surgicel® Versus Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding (HMB): Randomised Controlled Trial Unknown status NCT03176992 Phase 2 SURGICEL®
24 The Effect of Neoadjuvant Depot Medroxyprogesterone Acetate on Glandular Cellularity in Women With Complex Atypical Hyperplasia or Grade 1-2 Endometrial Adenocarcinoma Awaiting Hysterectomy Unknown status NCT02335203 Phase 2 Depot medroxyprogesterone acetate
25 Prospective Trial of Conservative Management of Atypical Endometrial Hyperplasia and Well to Moderately Differentiated Endometrial Carcinoma Using Megestrol Acetate Completed NCT00483327 Phase 2 Megestrol Acetate
26 Effect of Genistein on Endometrial Hyperplasia Completed NCT00453960 Phase 2 Norethisterone Acetate
27 Soy Estrogen Alternative Study (SEA) Completed NCT00000612 Phase 2 estrogens, conjugated
28 A Pilot Study on Fertility Conservative Treatment of Atypical Endometrial Hyperplasia in Singapore Recruiting NCT05492487 Phase 2 Mirena;Megace
29 Open-Label Randomized Phase II Trial of Megestrol Acetate With or Without Pterostilbene in Patients With Endometrial Cancer Scheduled for Hysterectomy Recruiting NCT03671811 Phase 2 Megestrol Acetate
30 Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination With the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer Recruiting NCT02397083 Phase 2 Everolimus
31 A Phase II Study of the Levonorgestrel Intrauterine Device (Mirena) to Treat Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Carcinoma Active, not recruiting NCT00788671 Phase 2
32 Pilot Study of Daily Exemestane in Women With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer Active, not recruiting NCT03300557 Phase 2 Exemestane
33 A Randomized Phase II Evaluation of Continuous Progestin Therapy vs. Sequential Progestin Therapy in the Treatment of Endometrial Intraepithelial Neoplasia (EIN) From a Referred Cohort of Atypical Endometrial Hyperplasia (AEH) or EIN Patients That Desire Uterine Preservation Terminated NCT00503581 Phase 2 Megestrol Acetate
34 A Two-Part Study of the Treatment of Atypical Endometrial Hyperplasia: Part A: A Prospective Study of Immediate Hysterectomy; Part B: A Randomized Phase II Study of Medroxyprogesterone Acetate Versus Depoprovera Terminated NCT00003179 Phase 2 medroxyprogesterone
35 Levonorgestrel Containing Intrauterine Device in the Treatment of Endometrial Hyperplasia Without Atypia Withdrawn NCT00123175 Phase 1, Phase 2
36 A Phase II Head-to-Head Comparison of Fertility-Sparing Approaches to Treat Complex Atypical Hyperplasia of the Edometrium: Megestrol Versus Levonorgestrel-Releasing Intrauterine System (LNG-IUS) Withdrawn NCT01943058 Phase 2 megestrol acetate
37 Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC) Active, not recruiting NCT00892866 Phase 1
38 Comparison of Dilatation & Curettage and Endometrial Aspiration Biopsy Accuracy in Patients Treated With Progestin for Endometrial Hyperplasia: A Korean Gynecologic Oncology Group Study Unknown status NCT02412072
39 Concurrent Endometrial Cancer With Endometrial Hyperplasia or Endometrial Intraepithelial Neoplasia - Focus on Risk Factors Analysis Unknown status NCT01273636
40 The Relation Between Serum Irisin Hormone Level and Endometrial Hyperplasia Unknown status NCT02903797
41 THE EFFECTIVENESS OF MONOPOLAR HOOC VERSUS PLASMAKINETIC BİPOLAR SPATULA USAGE DURING COLPOTOMY PROCESS IN PATIENTS UNDERGOİNG TOTAL LAPAROSCOPIC HYSTERECTOMY Unknown status NCT04191603
42 Role of Senescence in the Development of Endometrial Cancer Unknown status NCT03338985
43 Long-term Observation of Symptomatic Women With Uterine Fibroids Who Have Been Treated With Ulipristal Acetate: Findings on Symptomatology, Morphological Structure, Endometrial Patterns Unknown status NCT03972917
44 Metformin for the Treatment of Endometrial Hyperplasia Completed NCT01685762 Early Phase 1 Metformin
45 Women With Asymptomatic Endometrial Hyperplasia Completed NCT02100137
46 Pilot-study of OSCAR ENDO One Stop Assessment of Risk for Endometrial Hyperplasia and Cancer Completed NCT01961102
47 Correlation Between Hysteroscopic Diagnosis of Endometrial Hyperplasia and Histopathological Examination: a Prospective Cohort Study Completed NCT03917147
48 Preliminary Study of Endometrial Hyperplasia: Groundwork for a Study to Define an Optimal Classification of Endometrial Carcinoma Precursors Completed NCT00339651
49 Vaginal Micronized Progesterone or Levonorgestrel-releasing Intrauterine System (LNG-IUS) for Treatment of Non-atypical Endometrial Hyperplasia: A Prospective Randomized Trial Completed NCT03992937 Vaginal Micronized Progesterone
50 Office Hysteroscopy in the Infertility Work-out: the Role of Endometrial Hyperplasia in Southern Italian Women Completed NCT03965585

Search NIH Clinical Center for Endometrial Hyperplasia

Cochrane evidence based reviews: endometrial hyperplasia

Genetic Tests for Endometrial Hyperplasia

Anatomical Context for Endometrial Hyperplasia

Organs/tissues related to Endometrial Hyperplasia:

MalaCards : Uterus, Pituitary, Ovary, Breast, Lymph Node, Cervix, Bone

Publications for Endometrial Hyperplasia

Articles related to Endometrial Hyperplasia:

(show top 50) (show all 3409)
# Title Authors PMID Year
1
Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. 53 62
20107426 2010
2
Prognostic significance of estrogen and progesterone receptor expression in LNG-IUS (Mirena) treatment of endometrial hyperplasia: an immunohistochemical study. 53 62
20199355 2010
3
Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET. 53 62
19759112 2009
4
Involvement of Akt, Ras and cell cycle regulators in the potential development of endometrial hyperplasia in women with polycystic ovarian syndrome. 53 62
19631369 2009
5
Utility of PTEN expression of endometrial "surface epithelial changes" and underlying atypical endometrial hyperplasia. 53 62
19696618 2009
6
[Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions]. 53 62
20079187 2009
7
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. 53 62
19301987 2009
8
Correlation between PTEN expression and PI3K/Akt signal pathway in endometrial carcinoma. 53 62
19224164 2009
9
Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma. 53 62
19419940 2009
10
Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. 53 62
18720455 2008
11
Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma. 53 62
18788685 2008
12
Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review. 53 62
18528284 2008
13
PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. 53 62
18632658 2008
14
Labial aggressive angiomyxoma associated with endometrial hyperplasia and uterine leiomyoma: a case report and review of the literature. 53 62
18839858 2008
15
From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. 53 62
18287870 2008
16
Expression of retinoic acid receptors in human endometrial carcinoma. 53 62
18271925 2008
17
Distinctive FDG and FES accumulation pattern of two tamoxifen-treated patients with endometrial hyperplasia. 53 62
18250990 2008
18
Progressive derailment of cell cycle regulators in endometrial carcinogenesis. 53 62
17483252 2008
19
Letrozole as primary therapy for endometrial hyperplasia in young women. 53 62
17889878 2008
20
Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of rapamycin are associated with progesterone refractory endometrial hyperplasia. 53 62
17466036 2008
21
Coexpression index of estrogen receptor alpha mRNA isoforms in simple, complex hyperplasia without atypia, complex atypical hyperplasia and adenocarcinoma. 53 62
17561234 2007
22
Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement. 53 62
17197901 2007
23
Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. 53 62
17089036 2006
24
Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: Correlation with clinicopathologic parameters and biomarkers. 53 62
16980945 2006
25
Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. 53 62
17085648 2006
26
Androgen and estrogen receptors and co-regulators levels in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia. 53 62
16677694 2006
27
[Promoters of genes MTHFR from patients with hyperhomocysteinemia and PTEN from patients with malignant and benign endometrial and ovarian tumors]. 53 62
16909866 2006
28
Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications. 53 62
16575402 2006
29
[Expression and clinical significance of Beclin1 and PTEN in endometrial carcinoma]. 53 62
16764775 2006
30
[Expressions of aromatase protein and sex hormone receptor in endometrial lesions]. 53 62
16831363 2006
31
Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. 53 62
16325240 2006
32
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. 53 62
16633364 2006
33
The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. 53 62
16493257 2006
34
CYP17 genetic polymorphism in patients with endometrial hyperplasia and cancer. 53 62
16515644 2006
35
Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium. 53 62
17009632 2006
36
Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia. 53 62
16099019 2005
37
Eosinophilic cell change of the endometrium: a possible relationship to mucinous differentiation. 53 62
15803181 2005
38
Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression. 53 62
15948123 2005
39
Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma. 53 62
15882182 2005
40
Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium. 53 62
15863148 2005
41
Immunohistochemical detection of human telomerase reverse transcriptase (hTERT), topoisomerase IIalpha expression, and apoptosis in endometrial adenocarcinoma and atypical hyperplasia. 53 62
15782075 2005
42
Human telomerase RNA as endogenous control in endometrial tissue. 53 62
15823123 2005
43
Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables. 53 62
14740230 2005
44
Disorders in cytokine gene expression in endometrial hyperplasia and effect of hormone therapy. 53 62
16027816 2005
45
PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma. 53 62
15583796 2005
46
Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium. 53 62
15800680 2005
47
Differences in serum bisphenol a concentrations in premenopausal normal women and women with endometrial hyperplasia. 53 62
15644579 2004
48
Cellular retinol-binding protein-1 expression in endometrial stromal cells: physiopathological and diagnostic implications. 53 62
15500655 2004
49
Genetic derangements in the tumor suppressor gene PTEN in endometrial precancers as prognostic markers for cancer development: a population-based study from northern Norway with long-term follow-up. 53 62
15385114 2004
50
Multiple epithelial and nonepithelial tumors in hereditary nonpolyposis colorectal cancer: characterization of germline and somatic mutations of the MSH2 gene and heterogeneity of replication error phenotypes. 53 62
15350299 2004

Variations for Endometrial Hyperplasia

Expression for Endometrial Hyperplasia

Search GEO for disease gene expression data for Endometrial Hyperplasia.

Pathways for Endometrial Hyperplasia

Pathways related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 PTEN PGR NCOR1 MSH2 MLH1 KRAS
2 13.69 AR CDK2 CTNNB1 ESR1 ESR2 KRAS
3
Show member pathways
13.65 NCOR1 NCOA3 NCOA1 MMP26 KRAS ESR2
4
Show member pathways
13.57 RBP1 PTEN NCOR1 MSH6 MSH2 MLH1
5
Show member pathways
13.32 PTEN NCOR1 NCOA3 KRAS ESR2 ESR1
6
Show member pathways
12.92 PGR NCOR1 NCOA3 NCOA1 KRAS ESR2
7 12.78 PGR NCOR1 KRAS ESR1 CTNNB1
8
Show member pathways
12.66 PTEN MSH6 MSH2 MLH1 KRAS CTNNB1
9
Show member pathways
12.57 MSH6 MSH2 ESR2 ESR1 CDK2
10 12.49 CDK2 MKI67 MLH1 MSH2 MSH6
11 12.38 NCOR1 NCOA3 NCOA1 AR
12
Show member pathways
12.38 MSH6 MSH2 MLH1 CDK2
13
Show member pathways
12.29 ESR1 ESR2 NCOA1 NCOA3 NCOR1
14
Show member pathways
12.27 CDK2 ESR1 NCOA1 NCOA3 NCOR1 PGR
15
Show member pathways
12.19 PTEN PGR NCOA3 NCOA1 KRAS ESR2
16 12.13 MSH6 MSH2 MLH1 KRAS CTNNB1
17
Show member pathways
12.06 PTEN NCOR1 NCOA1 CTNNB1 AR
18
Show member pathways
12.05 PGR NCOR1 KRAS ESR1
19
Show member pathways
11.95 PGR NCOR1 ESR2 ESR1 AR
20 11.87 PTEN KRAS CTNNB1
21 11.87 KRAS ESR2 ESR1 AR
22 11.85 PTEN MSH2 MLH1 CDK2
23 11.79 RBP1 MSH6 CDK2
24 11.75 CDK2 MLH1 MSH2
25 11.69 CTNNB1 KRAS PTEN
26
Show member pathways
11.67 NCOA3 NCOA1 ESR1
27 11.66 PTEN ESR1 CTNNB1
28 11.64 NCOR1 NCOA1 ESR1 CDK2 AR
29 11.5 PTEN NCOA3 MSH6 MSH2 KRAS ESR1
30 11.38 NCOA3 ESR1 AR
31 11.34 PTEN MSH6 MSH2 CDK2
32 11.3 PGR ESR2 ESR1
33 11.25 MSH6 MSH2 MLH1
34 11.25 PGR NCOR1 NCOA3 NCOA1 ESR2 ESR1
35
Show member pathways
11.21 RBP1 NCOA3 NCOA1
36 11.21 CYP19A1 ESR2 MLH1 NCOR1 PGR
37 11.17 NCOA3 NCOA1 ESR1
38 11.13 KRAS ESR2 ESR1
39 10.88 NCOA3 NCOA1 ESR2
40 10.8 PGR ESR1
41 10.18 ESR2 ESR1 CYP19A1

GO Terms for Endometrial Hyperplasia

Cellular components related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 10.33 AR CDK2 CTNNB1 ESR1 ESR2 MKI67
2 chromatin GO:0000785 10.16 PGR NCOR1 NCOA3 NCOA1 MSH6 ESR2
3 mismatch repair complex GO:0032300 9.5 MSH2 MLH1
4 condensed chromosome GO:0000793 9.35 MLH1 MKI67 CDK2
5 MutSalpha complex GO:0032301 8.92 MSH6 MSH2

Biological processes related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA-binding transcription factor activity GO:0051091 10.14 CTNNB1 ESR1 ESR2 PTEN
2 cellular response to estradiol stimulus GO:0071392 10.02 NCOA3 ESR2 ESR1
3 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.97 MSH6 MSH2 MLH1
4 mismatch repair GO:0006298 9.95 MSH6 MSH2 MLH1
5 intracellular estrogen receptor signaling pathway GO:0030520 9.88 ESR2 ESR1 AR
6 positive regulation of helicase activity GO:0051096 9.86 MSH6 MSH2
7 isotype switching GO:0045190 9.85 MSH6 MSH2 MLH1
8 positive regulation of isotype switching to IgA isotypes GO:0048298 9.83 MSH2 MLH1
9 epithelial cell differentiation involved in prostate gland development GO:0060742 9.8 CTNNB1 AR
10 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.76 AR PGR
11 histone modification GO:0016570 9.74 NCOA3 NCOA1 CDK2
12 positive regulation of epithelial cell proliferation involved in prostate gland development GO:0060769 9.73 AR CTNNB1
13 somatic hypermutation of immunoglobulin genes GO:0016446 9.73 MLH1 MSH2 MSH6
14 maintenance of DNA repeat elements GO:0043570 9.69 MSH6 MSH2
15 prostate gland growth GO:0060736 9.63 PTEN CYP19A1 AR
16 negative regulation of miRNA maturation GO:1903799 9.58 NCOR1 ESR1
17 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.5 MSH2 MLH1
18 somatic recombination of immunoglobulin gene segments GO:0016447 9.35 MSH6 MSH2 MLH1
19 intracellular steroid hormone receptor signaling pathway GO:0030518 9.23 PGR ESR2 ESR1 AR

Molecular functions related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 10.28 AR CTNNB1 ESR1 MLH1 MSH2 MSH6
2 RNA polymerase II-specific DNA-binding transcription factor binding GO:0061629 10.1 NCOR1 NCOA3 NCOA1 CTNNB1 AR
3 transcription coactivator binding GO:0001223 10.04 PGR ESR1 AR
4 nuclear estrogen receptor binding GO:0030331 10.03 NCOA1 ESR1 CTNNB1
5 nuclear receptor activity GO:0004879 9.97 PGR ESR2 ESR1 AR
6 lipid binding GO:0008289 9.95 RBP1 PTEN PGR ESR2 ESR1 AR
7 ATP-dependent DNA damage sensor activity GO:0140664 9.93 MSH6 MSH2 MLH1
8 nuclear steroid receptor activity GO:0003707 9.91 PGR ESR2 ESR1
9 MutLalpha complex binding GO:0032405 9.88 MSH6 MSH2
10 oxidized purine DNA binding GO:0032357 9.88 MSH6 MSH2
11 nuclear receptor binding GO:0016922 9.86 CTNNB1 NCOA1 NCOA3 NCOR1
12 estrogen response element binding GO:0034056 9.85 ESR2 ESR1
13 nuclear estrogen receptor activity GO:0030284 9.84 ESR1 ESR2
14 single guanine insertion binding GO:0032142 9.83 MSH2 MSH6
15 single thymine insertion binding GO:0032143 9.78 MSH6 MSH2
16 steroid binding GO:0005496 9.76 PGR ESR2 ESR1 AR
17 mismatched DNA binding GO:0030983 9.72 MSH6 MSH2 MLH1
18 enzyme binding GO:0019899 9.62 PTEN PGR NCOA1 MSH6 MSH2 MLH1
19 guanine/thymine mispair binding GO:0032137 9.43 MSH6 MSH2 MLH1

Sources for Endometrial Hyperplasia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....